BNK InvestJun 23, 2026, 12:00 AMnasdaq
S&P 500 Movers: SNDK, AXON
In early trading on Tuesday, shares of Axon Enterprise topped the list of the day's best performing components of the S&P 500 index, trading up 4.5%. Year to date, Axon Enterprise has lost about 24.6% of its value.
And the worst performing S&P 500 component thus far on
Open articleZacksJun 16, 2026, 12:00 AMnasdaq
Abbott's CGM Growth Story Stays Intact Despite Q1 Moderation
ABT's CGM sales growth slows in Q1, but management sees a return to double-digit gains as Libre expands with new products and AI tools.
Open articleBNK InvestJun 8, 2026, 12:00 AMnasdaq
Monday 6/8 Insider Buying Report: PODD, ADC
Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned cash to make a purchase, is that they expect to make money. Today we
Open articleRTTNewsJun 8, 2026, 12:00 AMnasdaq
Insulet Presents Positive Pivotal Trial Data For Omnipod 6 And FLC In Treating Diabetes
(RTTNews) - Insulet Insult Corporation (PODD), a medical devices company, on Saturday released results for the STRIVE trial for Omnipod 6, an automated insulin delivery system, and the EVOLUTION 3 feasibility study for the fully-closed loop system in treating type-2 diabetes. The
Open articleZacksJun 5, 2026, 12:00 AMnasdaq
Why Is Insulet (PODD) Down 8.7% Since Last Earnings Report?
Insulet (PODD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Open articleThe Motley FoolJun 4, 2026, 12:00 AMnasdaq
DexCom vs. Insulet: Which Diabetes Stock Is a Better Buy in 2026?
Key PointsDexCom is a leading innovator in the continuous glucose monitoring market with a global footprint across 52 countries.
Open articleZacksJun 3, 2026, 12:00 AMnasdaq
Tandem Diabetes Valuation: Is 1.1x Sales a Buy?
TNDM trades near 1.1x forward sales as it shifts to pharmacy pay-as-you-go and expands Europe, with a $21 target tied to 1.3x sales.
Open articleZacksJun 2, 2026, 12:00 AMnasdaq
TNDM Stock: What to Know About Tandem's 2026 Reset
Tandem Diabetes' Q1 beat, fatter margins and positive cash flow fuel its 2026 reset as it shifts more U.S. pump starts to pay-as-you-go pharmacy.
Open articleZacksJun 2, 2026, 12:00 AMnasdaq
Insulet (PODD) is a Top-Ranked Growth Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Open articleZacksMay 28, 2026, 12:00 AMnasdaq
PODD Stock: What a Hold Rating Says at a $163 Target
Insulet earns a short-term Hold as outlook rises; a $163 sales-based target tests whether growth can beat 2026 volatility.
Open articleZacksMay 27, 2026, 12:00 AMnasdaq
PODD and Omnipod 5: What's Driving Insulet's 2026 Growth
Insulet's Omnipod 5 drives a Q1 beat and raised 2026 outlook as upgrades and global rollout expand access - while correction costs loom.
Open articleBNK InvestMay 27, 2026, 12:00 AMnasdaq
S&P 500 Movers: BSX, MGM
In early trading on Wednesday, shares of MGM Resorts International topped the list of the day's best performing components of the S&P 500 index, trading up 7.4%. Year to date, MGM Resorts International registers a 13.2% gain.
And the worst performing S&P 500 component
Open article